Assay Report
Methods · Standard Curves · QC · Results
Specialized B-cell Enzyme-Linked ImmunoSpot (ELISpot) and FluoroSpot bioanalytical testing services for enumerating total and antigen-specific antibody-secreting cells (ASCs), circulating plasmablasts, and resting memory B-cell frequencies in human, non-human primate (NHP), and rodent peripheral blood mononuclear cells (PBMCs), splenocytes, and bone marrow aspirates down to 1 in 1,000,000 single cells.
By measuring functional antibody secretion across IgG, IgM, and IgA isotypes following standardized polyclonal stimulation (R848 + recombinant IL-2), our platform evaluates vaccine humoral durability, memory B-cell recall potential, and therapeutic antibody immunogenicity.
Universal experimental design dimensions ensuring sound biological comparison and analytical specificity.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Polyclonal Differentiation Regimen | TLR7/8 agonist R848 (1.0 μg/mL) combined with recombinant human IL-2 (10 ng/mL) for 3–5 days | Efficiently drives resting memory B cells into antibody-secreting plasma cells without altering antigen specificity. |
| Antigen-Specific vs Total Ig Ratio | Parallel plating on target antigen-coated wells vs. anti-human/mouse total IgG/IgM/IgA capture wells | Normalizes antigen-specific spot counts against total B-cell differentiation efficiency, yielding accurate relative memory frequencies (%). |
| Capture Antigen Coating Quality | High-purity recombinant proteins, viral glycoproteins, or haptenated antigens (>95% purity) | Ensures high-affinity antibody-binding capacity on PVDF membranes and eliminates non-specific background spots. |
| Spontaneous Plasmablast Gating | Direct ex vivo plating without 4-day pre-culture to capture transient circulating plasmablast waves | Detects acute post-vaccination or post-infection plasmablast bursts peaking at Day 7–10 post-immunization. |
| Control Arm Configuration | Negative control (uncoated / BSA-blocked wells <5 SFU/well), Unstimulated PBMC controls, Positive donor standards | Validates reagent specificity, confirms effective polyclonal activation, and eliminates non-specific protein adhesion. |
Validated B-cell testing configurations across vaccine memory, plasmablasts, and mucosal immunity.
| Assay Capability & Isotype Scope | Target Antigens & Model Systems | Primary Readout & Metrics | Dedicated Research Application |
|---|---|---|---|
| Vaccine-Specific Memory B Cell Frequency | Recombinant viral spike/RBD, influenza HA, bacterial toxoids | Antigen-specific IgG/IgM/IgA SFU | Quantifying memory B-cell reservoir depth and durability across mRNA, protein, and viral-vectored vaccine studies. |
| Total Immunoglobulin ASC Capacity | Total IgG, IgM, IgA isotypes (anti-Ig capture) | Total ASC spots per 10^5 cells | Benchmarking baseline B-cell competence, polyclonal responsiveness, and B-cell immunodeficiency status. |
| Mucosal & Secretory IgA Profiling | Mucosal pathogens, respiratory antigens, gut microbiota | IgA1 & IgA2 spot-forming units | Evaluating mucosal vaccine delivery, oral immunizations, and mucosal barrier humoral memory. |
| Autoimmune Autoreactive B Cell Assays | Autoantigens (dsDNA, Sm/RNP, citrullinated peptides, MOG) | Autoreactive IgG/IgM ASC counts | Tracking pathogenic autoreactive B-cell expansion and evaluating B-cell depletion therapies (anti-CD20 mAbs). |
| Bone Marrow Long-Lived Plasma Cells | Bone marrow aspirates & tissue-resident splenocytes | Direct spontaneous ASC enumeration | Assessing true lifelong humoral memory reserves and bone marrow plasma cell homing in preclinical models. |
Evaluating cellular resolution, memory detection, and throughput across humoral platforms.
| Technical Dimension | B Cell ELISpot (Our Service) | Serum Titration ELISA | Flow Cytometry B-Cell Phenotyping |
|---|---|---|---|
| Primary Measurement | Frequency of functional antibody secretors | Total accumulated circulating antibody | Surface phenotyping & receptor binding |
| Memory B Cell Detection | Direct (Quantifies ex vivo differentiated ASCs) | No (Blind to non-secreting memory) | Indirect (Fluorophore-antigen binding) |
| Single-Cell Functional Readout | Yes (Direct SFU per million cells) | No (Bulk concentration sum) | Non-functional (Binding only) |
| Isotype Deconvolution | Single-cell IgG, IgM, IgA spot resolution | Parallel serum dilution plates | Complex multi-color surface panels |
| Sensitivity Threshold | 1 in 100,000 to 1 in 1,000,000 | Nanogram/mL detection limit | ~0.05% (Requires high cell input) |
| Biological Sample Required | Viable PBMCs, Splenocytes, Bone Marrow | Serum, Plasma, or Mucosal Fluid | Viable PBMCs or Splenocytes |
Standardized operating procedures, automated spot deconvolution, and rigorous quality gating.
Standardized 4-day R848 (1.0 μg/mL) and recombinant IL-2 (10 ng/mL) stimulation SOPs ensure robust memory B-cell expansion and high total IgG spot counts.
Advanced optical filtering distinguishes tight, high-intensity true antibody spots from non-specific background smearing, quantifying accurate ASC counts.
Parallel plating against total Ig capture wells normalizes antigen-specific spot counts against total differentiated B cells, eliminating donor-to-donor variation.
Thawing viable donor PBMCs; culturing with R848 and IL-2 for 72–96 hours at 37°C to differentiate memory B cells into ASCs.
Coating low-fluorescent PVDF membrane plates with target antigen (e.g., recombinant protein) or anti-Ig capture antibodies.
Washing stimulated cells and plating 100,000–500,000 cells per well in antigen-coated plates; incubating overnight at 37°C.
Washing cells and incubating with biotinylated or fluorophore-conjugated anti-IgG, anti-IgM, or anti-IgA detection antibodies.
Automated acquisition on Mabtech readers, spot counting, calculation of % antigen-specific B-cell frequencies, and reporting.
Standardized pre-analytical handling protocols ensuring optimal memory B-cell differentiation and high-affinity antibody secretion.
| Pre-Analytical Parameter | Why It Matters for B-Cell Memory Assays | Intake Specification & Recommendation |
|---|---|---|
| PBMC Isolation Timing | Delayed blood processing causes granulocyte contamination and impairs B-cell proliferative responsiveness. | Isolate PBMCs via density gradient centrifugation (Ficoll-Paque) within 8 hours of collection. |
| Cryopreservation Quality | Suboptimal freezing protocols damage fragile memory B-cell subsets, reducing post-thaw differentiation capacity. | Resuspend in pre-chilled freezing medium (90% FBS + 10% DMSO or CryoStor CS10); freeze at -1°C/min. |
| Post-Thaw Cell Viability | Dying cells release DNA and non-specific proteases, increasing background noise and suppressing B-cell expansion. | Cell viability must exceed 80%; include a 1–2 hour recovery resting phase at 37°C prior to stimulation. |
| Input Cell Quantity | 4-day polyclonal pre-culture and multi-antigen plating require adequate starting cell numbers. | Provide minimum 10–15 × 10^6 cryopreserved viable cells per donor/sample. |
| Polyclonal Reagent Purity | Suboptimal R848 or degraded IL-2 leads to incomplete B-cell differentiation and underestimation of memory frequencies. | Use verified single-use aliquots of endotoxin-free R848 and bioactive recombinant human IL-2. |
Applying B-cell ELISpot across vaccine durability, mucosal IgA immunity, and autoreactive B-cell tracking.
Enumerate antigen-specific IgG memory B-cell frequencies months or years post-vaccination to evaluate long-term humoral protection.
Quantify antigen-specific IgA antibody-secreting cells in mucosal tissues (Peyer's patches, mesenteric lymph nodes) and blood.
Track the acute expansion and peak circulation window of antigen-specific plasmablasts (Day 7 post-immunization).
Quantify autoreactive memory B cells and plasmablasts directed against self-antigens in lupus, arthritis, and MS models.
Monitor depletion and reconstitution kinetics of memory B cells following anti-CD20 or anti-CD19 therapeutic dosing.
Screen memory B-cell frequencies capable of binding diverse variant antigen panels (e.g., viral mutant spike proteins).
Standardized bioanalytical documentation, annotated spot images, and senior immunologist consultation.
Key peer-reviewed publications establishing polyclonal B-cell differentiation and memory quantification.
Study Design Takeaway: Landmark paper establishing the standardized R848 + IL-2 polyclonal stimulation protocol for differentiating and enumerating human memory B cells via ELISpot.
Study Design Takeaway: Demonstrates that memory B-cell ELISpot reveals long-lived protective humoral memory reserves that persist even when circulating serum titers wane.
Study Design Takeaway: Validates multi-color FluoroSpot for simultaneously resolving distinct immunoglobulin isotypes (IgG/IgM/IgA) from the same sample well at single-cell resolution.
Study Design Takeaway: Outlines clinical methodologies for enumerating circulating antibody-secreting plasmablasts and homing receptors following mucosal vaccination.
Addressing common project planning, cell handling, and assay selection inquiries.
Resting memory B cells circulate in a quiescent, non-secreting state and cannot be detected by direct ex vivo plating. Pre-culturing PBMCs with TLR7/8 agonist R848 and recombinant IL-2 for 72–96 hours differentiates memory B cells into actively secreting plasmablasts without altering their original antigen specificity.
Yes. Spontaneous antibody-secreting cells (plasmablasts) circulate transiently in peripheral blood (peaking at Day 7 post-immunization or infection). Plating fresh PBMCs directly without 4-day pre-stimulation specifically enumerates these active in vivo plasmablasts.
In every assay, cells are plated in parallel on target antigen-coated wells and anti-human/mouse total Ig capture wells. The frequency is reported as: % Antigen-Specific B Cells = (Antigen-Specific SFU / Total IgG SFU) × 100. This normalizes for donor-to-donor variation in total B-cell numbers and in vitro differentiation efficiency.
Because the assay involves a 4-day pre-culture step and parallel total Ig controls, we typically recommend providing 10–15 × 10^6 cryopreserved viable PBMCs per donor/sample.
Yes. Using our multi-color B-cell FluoroSpot configuration, distinct fluorophores are paired with anti-IgG, anti-IgM, and anti-IgA detection antibodies to resolve all three isotypes in the same sample well.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical vaccine evaluation, humoral memory research, and translational research cohorts, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×